ReviewMayo Clinic proceedings2020
SARS-CoV-2 Vaccine Development: Current Status.
Review in Mayo Clinic proceedings, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed.
- Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trial.Human vaccines & immunotherapeutics · 2023Trial
- Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19.Nature communications · 2022Trial
- Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19.Nature medicine · 2021Trial
- Phase III Trials in India: A Comprehensive Analysis of the Clinical Trials Registry-India.Cureus · 2026Article
- Adverse reactions following first three doses of the BNT162b2 mRNA COVID-19 vaccine: A prospective cohort study on relationships with individual characteristics and previous experience of adverse reactions.Human vaccines & immunotherapeutics · 2025Article
- Evolutionary Insight into Fatal Human Coronaviruses (hCoVs) with a Focus on Circulating SARS-CoV-2 Variants Under Monitoring (VUMs).Biomedicines · 2025Review
- Understanding vaccine hesitancy through the lens of trust and the 3C model: evidence from Chinese General Social Survey 2021.Frontiers in public health · 2025Article
- Exploring the emerging technologies and trends of infectious diseases in the post-epidemic era.Frontiers in public health · 2025Article
- Motifs in SARS-CoV-2 evolution.RNA (New York, N.Y.) · 2023Article
- Development of SARS-CoV-2 Vaccine: Challenges and Prospects.Diseases (Basel, Switzerland) · 2023Review
- SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies.NPJ vaccines · 2023Article
- An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals.iScience · 2023Article
- Evaluation of Immunogenicity and Clinical Protection of SARS-CoV-2 S1 and N Antigens in Syrian Golden Hamster.Vaccines · 2022Article
- Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities.NPJ vaccines · 2022Article
- Coronavirus disease 2019 (COVID-19) vaccines: A concise review.Oral diseases · 2022Review
- Potential of antibody pair targeting conserved antigenic sites in diagnosis of SARS-CoV-2 variants infection.Journal of virological methods · 2022Article
- Lipid nanoparticles in the development of mRNA vaccines for COVID-19.Journal of drug delivery science and technology · 2022Review
- Point-of-Care Ultrasound Is a Valuable Modality During Mass COVID-19 Vaccination Campaigns.Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine · 2022Article
- An overview on inactivated and live-attenuated SARS-CoV-2 vaccines.Journal of clinical laboratory analysis · 2022Review
- First computational design using lambda-superstrings and in vivo validation of SARS-CoV-2 vaccine.Scientific reports · 2022Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the midst of the severe acute respiratory syndrome coronavirus 2 pandemic and its attendant morbidity and mortality, safe and efficacious vaccines are needed that induce protective and long-lived immune responses. More than 120 vaccine candidates worldwide are in various preclinical and phase 1 to 3 clinical trials that include inactivated, live-attenuated, viral-vectored replicating and nonreplicating, protein- and peptide-based, and nucleic acid approaches. Vaccines will be necessary both for individual protection and for the safe development of population-level herd immunity. Public-private partnership collaborative efforts, such as the Accelerating COVID-19 Therapeutic Interventions and Vaccines mechanism, are key to rapidly identifying safe and effective vaccine candidates as quickly and efficiently as possible. In this article, we review the major vaccine approaches being taken and issues that must be resolved in the quest for vaccines to prevent coronavirus disease 2019. For this study, we scanned the PubMed database from 1963 to 2020 for all publications using the following search terms in various combinations: SARS, MERS, COVID-19, SARS-CoV-2, vaccine, clinical trial, coronavirus, pandemic, and vaccine development. We also did a Web search for these same terms. In addition, we examined the World Health Organization, Centers for Disease Control and Prevention, and other public health authority websites. We excluded abstracts and all articles that were not written in English.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.